Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on March 16, 2020. The filing reports the company's financial results for the fourth quarter and the full year ended December 31, 2019. The company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Capital Market under the symbol ARPO.
Key Financial Metrics
The filing text serves as a notification of results and does not contain specific numerical data for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained in the press release furnished as Exhibit 99.1, which is not included in the provided text.
Material Changes
The filing text does not provide specific details regarding material changes versus prior periods. It only confirms the announcement of the Q4 and full-year 2019 results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished under Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the body of this 8-K text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release), as they are absent from this summary text.
- Confirm the company name is Aerpio Pharmaceuticals, Inc., noting a discrepancy with the metadata label "Whitehawk Therapeutics, Inc."
- Review the full press release for any forward-looking statements or clinical trial updates not captured in this notification filing.